Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Published	Pages	Publisher	Report code
Jul 2022	62	Global Markets Direct	ASDR-608295

Published: Jul 2022 - Pages : 62 - Publisher : Global Markets Direct - Report code : ASDR-608295

AlphaVax Inc
Helocyte Biosciences Inc
Hookipa Pharma Inc
Immunomic Therapeutics Inc
Moderna Inc
VBI Vaccines Inc